Showing 1 - 5 results of 5 for search 'Jens Tijtgat', query time: 0.03s Refine Results
  1. 1
    Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

    Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Pa... by Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns

    Published 2020-11-01
    Get full text
    Article
  2. 2
    Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

    Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory adva... by Bart Neyns, Angela Vasaturo, Julia Katharina Schwarze, Gil Awada, Ramses Forsyth, Jens Tijtgat, Louise Cras, Christopher Bagnall, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet

    Published 2022-09-01
    Get full text
    Article
  3. 3
    Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

    Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous... by Bart Neyns, Julia Katharina Schwarze, Karen Willard-Gallo, Ramses Forsyth, Jens Tijtgat, Sandra Tuyaerts, Ivan Van Riet, Steven Raeymaeckers, Xenia Geeraerts, Latoya Stevens, Manon Vounckx, Iris Dirven, Anais Boisson

    Published 2024-01-01
    Get full text
    Article
  4. 4
    694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

    694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in sol... by Bart Neyns, Bart Ilsen, Jens Tijtgat, Frederik Vandenbroucke, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Xenia Geeraerts, Latoya Stevens, Manon Vounckx, Iris Dirven, Steven Raemaeckers, Selma Ben Mustapha, Jens Van Loon, Lore Decoster, Mark De Ridder

    Published 2023-11-01
    Article
  5. 5
    Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

    Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial by Mark Kockx, Bart Neyns, Julia Katharina Schwarze, Gil Awada, Laura Seynaeve, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Johnny Duerinck, Ramses Forsyth, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Louise Cras, Nicky D’Haene, Ben Caljon, Isabelle Salmon, Michaël Bruneau, Sonia Van Dooren

    Published 2021-06-01
    Get full text
    Article

Search Tools: